Stocks making the biggest moves premarket: UBER, GAP, CAT

People walk by a Gap retail store on August 24, 2022 in Beijing, China.

VCG | Getty Images

Check out the companies making headlines before the bell on Tuesday.

SoFi Technologies — The financial technology stock dropped 3.7% after KBW analyst Michael Perito downgraded the stock from underperform from market perform. Perito hiked his price target for shares by $2 to $7.50, however, which still implies shares can fall 34.5% from Monday’s closing price. 

Estee Lauder — The beauty stock shed 1.1% following a Barclays downgrade to neutral from buy. The firm said difficulties in China could weigh on the business in the near-term.

Gap — The retail stock climbed nearly 4% after Barclays upgraded Gap to overweight from equal weight. Analyst Adrienne Yih assigned a $13 price target to the company, which suggests shares could rally 26.2% from Monday’s close. The firm also upgraded retailers American Eagle, Bath & Body Works and Tapestry to overweight. Each of those are up more than 2% in early morning trading.

Incyte — Shares rose 2% after Incyte beat analysts’ expectations in its latest results. The pharmaceutical company reported second-quarter revenue of $954.6 million, exceeding the FactSet consensus estimate of $909.7 million. Per-share adjusted earnings came in at $0.99, higher than the forecasted $0.72 per share. CEO Herve Hoppenot cited double-digit growth in Jakafi (ruxolitinib), a treatment for blood cancer.

Uber — Shares of the ride-hailing giant rose more than 2% in premarket trading after the company reported second-quarter results that missed analysts’ expectations for revenue but offered rosy guidance for the third quarter. CEO Dara Khosrowshahi said the company achieved two major milestones during the quarter: its first quarter of free cash flow over $1 billion and its first GAAP operating profit. 

Caterpillar — Shares of the manufacturing company gained 1.4% after reporting better-than-expected earnings and revenue. Caterpillar warned of potential decline in sales and margins for the third quarter, however.

Merck — Shares of the pharmaceutical giant rose nearly 2% premarket after the company reported second-quarter revenue that topped expectations, driven by sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. Merck also posted a narrower than expected loss for the quarter.

Pfizer — The stock shed more than 1% in early morning trading after Pfizer reported second-quarter adjusted revenue that beat expectations but posted revenue that fell short of Wall Street’s estimates. The company’s revenue miss was caused by a decline in Covid product sales.

ZoomInfo Technologies — Shares sank by nearly 20% in premarket trading after the data company reported a weak outlook for third-quarter revenue. ZoomInfo, which posted results after Monday’s close, said it anticipates $309 million to $312 million in revenue, falling short of analysts’ expectations of $326 million as gauged by Refinitiv. ZoomInfo’s revenue in the latest quarter also missed expectations, coming in at $309 million, while analysts estimated $311 million.

Toyota Motor — The automaker added about 2% after reporting operating income of 1.12 million yen ($7.84 billion) for the fiscal first quarter, 94% higher than a year prior. That topped the 9.878 trillion yen expected from analysts polled by Refinitiv.

Arista Networks — Shares advanced 13.6% in premarket trading after the company reported after the bell Monday that its quarterly earnings topped analysts’ expectations. Arista posted adjusted earnings of $1.58 per share, versus consensus analyst estimates of $1.44 per share, according to Refinitiv. Revenue also came in higher than expected at $1.46 billion, compared to analyst expectations of $1.38 billion.

— CNBC’s Tanaya Macheel, Alex Harring, Yun Li, Sarah Min, and Michelle Fox Theobald contributed reporting.

Share with your friends!

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest stocks updates
straight to your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.